Cargando…

The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia

SIMPLE SUMMARY: RNA splicing factors are frequently altered in cancer and have been found mutated or deregulated in myeloid malignancies, justifying the growing interest in new therapeutic strategies. We recently showed that the DNA methylation alterations of CD34(+)CD15(−) chronic myeloid leukaemia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lebecque, Benjamin, Bourgne, Celine, Munje, Chinmay, Berger, Juliette, Tassin, Thomas, Cony-Makhoul, Pascale, Guerci-Bresler, Agnès, Johnson-Ansah, Hyacinthe, Liu, Wei, Saugues, Sandrine, Tchirkov, Andrei, Vetrie, David, Copland, Mhairi, Berger, Marc G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563771/ https://www.ncbi.nlm.nih.gov/pubmed/36230624 http://dx.doi.org/10.3390/cancers14194695

Ejemplares similares

Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34(−) and immature CD34(+) cells
por: Berger, Marc G., et al.
Publicado: (2021)

DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34(+) CD15(−) cells in early chronic‐phase chronic myeloid leukemia
por: Maupetit‐Mehouas, Stéphanie, et al.
Publicado: (2018)

Tyrosine Kinase Inhibitor Independent Gene Expression Signature in CML Offers New Targets for LSPC Eradication Therapy
por: Gómez-Castañeda, Eduardo, et al.
Publicado: (2022)

DNA Methylation and Intra-Clonal Heterogeneity: The Chronic Myeloid Leukemia Model
por: Lebecque, Benjamin, et al.
Publicado: (2021)

Using healthcare claims data to analyze the prevalence of BCR‐ABL‐positive chronic myeloid leukemia in France: A nationwide population‐based study
por: Foulon, Stéphanie, et al.
Publicado: (2019)

Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity
por: Copland, Mhairi
Publicado: (2022)

Freezing Does Not Alter Sperm Telomere Length despite Increasing DNA Oxidation and Fragmentation
por: Gouhier, Charlène, et al.
Publicado: (2023)

Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib
por: Genthon, Alexis, et al.
Publicado: (2020)

ENOX2 NADH Oxidase: A BCR-ABL1-Dependent Cell Surface and Secreted Redox Protein in Chronic Myeloid Leukemia
por: Baykal, Seda, et al.
Publicado: (2023)

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial
por: Dulucq, Stéphanie, et al.
Publicado: (2022)

Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal
por: Toofan, Parto, et al.
Publicado: (2018)

Applicability of the long‐term uncertainty in measurement (LTUM) method for analytical performance assessment in clinical cytometry laboratories
por: Dannus, Louis‐Thomas, et al.
Publicado: (2021)

Spliceosome Database: a tool for tracking components of the spliceosome
por: Cvitkovic, Ivan, et al.
Publicado: (2013)

Accuracy of chitotriosidase activity and CCL18 concentration in assessing type I Gaucher disease severity. A systematic review with meta-analysis of individual participant data
por: Raskovalova, Tatiana, et al.
Publicado: (2020)

Consensus on BCR‐ABL1 reporting in chronic myeloid leukaemia in the UK
por: Cross, Nicholas C. P., et al.
Publicado: (2018)

Structures of the human pre-catalytic spliceosome and its precursor spliceosome
por: Zhan, Xiechao, et al.
Publicado: (2018)

Hormonal Therapy Resistance and Breast Cancer: Involvement of Adipocytes and Leptin
por: Delort, Laetitia, et al.
Publicado: (2019)

Human spliceosomal snRNA sequence variants generate variant spliceosomes
por: Mabin, Justin W., et al.
Publicado: (2021)

Spliceosome assembly and regulation: insights from analysis of highly reduced spliceosomes
por: Black, Corbin S., et al.
Publicado: (2023)

A Novel Therapeutic Strategy for the Treatment of Glioma, Combining Chemical and Molecular Targeting of Hsp90α
por: Mehta, Adi, et al.
Publicado: (2011)

Mast cell density and its clinical relevance in Waldenström's macroglobulinemia
por: Lemal, Richard, et al.
Publicado: (2022)

Challenging the spliceosome machine
por: Weir, Michael, et al.
Publicado: (2006)

Structure of spliceosomal ribonucleoproteins
por: Krummel, Daniel Aaron Pomeranz, et al.
Publicado: (2010)

CryoEM structures of two spliceosomal complexes: starter and dessert at the spliceosome feast
por: Nguyen, Thi Hoang Duong, et al.
Publicado: (2016)

Patterns of conservation of spliceosomal intron structures and spliceosome divergence in representatives of the diplomonad and parabasalid lineages
por: Hudson, Andrew J., et al.
Publicado: (2019)

Meta-Analysis and Gene Set Analysis of Archived Microarrays Suggest Implication of the Spliceosome in Metastatic and Hypoxic Phenotypes
por: De Meulder, Bertrand, et al.
Publicado: (2014)

The spliceosome as target for anticancer treatment
por: van Alphen, R J, et al.
Publicado: (2009)

Origin and evolution of spliceosomal introns
por: Rogozin, Igor B, et al.
Publicado: (2012)

Spliceosome Mutations in Uveal Melanoma
por: Nguyen, Josephine Q.N., et al.
Publicado: (2020)

Spliceosomal snRNA Epitranscriptomics
por: Morais, Pedro, et al.
Publicado: (2021)

The impact of spliceosome mutations in MDS
por: Boultwood, Jacqueline, et al.
Publicado: (2019)

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
por: Horne, G. A., et al.
Publicado: (2020)

CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy
por: Kinstrie, Ross, et al.
Publicado: (2020)

Correction: CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy
por: Kinstrie, Ross, et al.
Publicado: (2020)

Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended
por: Huet, Sarah, et al.
Publicado: (2014)

Computational screen for spliceosomal RNA genes aids in defining the phylogenetic distribution of major and minor spliceosomal components
por: López, Marcela Dávila, et al.
Publicado: (2008)

Transcriptomic and genomic identification of spliceosomal genes from Euglena gracilis : Identification of Euglena gracilis spliceosomal genes
por: Gao, Pingwei, et al.
Publicado: (2023)

Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
por: Canet, Jim, et al.
Publicado: (2021)

Hedgehog signaling in cancer stem cells: a focus on hematological cancers
por: Campbell, Victoria, et al.
Publicado: (2015)

Minor spliceosome, major surprise: it's cytoplasmic
por: Robinson, Richard
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_jqtiadl2l1t26hs0nul25uoagp